In summary, the analysis of MET gene abnormalities in patients with locally advanced or advanced NSCLC should be a routine diagnosis in subjects without other predictive factors such as ROS1 or ALK gene rearrangements and EGFR gene mutations. This evidence concerns the gene EGFR and non-small cell lung carcinoma.